The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure. (27th June 2022)

• Record Type: Journal Article
• Authors: Pinsino, Alberto; Fabbri, Matteo; Braghieri, Lorenzo; Bohn, Bruno; Gaudig, Antonia J.; Kim, Andrea; Takeda, Koji; Naka, Yoshifumi; Sayer, Gabriel T.; Uriel, Nir; Demmer, Ryan T.; Faillace, Robert T.; Husain, Syed A.; Mohan, Sumit; Colombo, Paolo C.; Yuzefpolskaya, Melana
• Is Part Of: ESC heart failure. Volume 9:Number 5(2022)
• Page Start: 3139
• Page End: 3148
• Publication Date: 2022-06-27
• Subjects: Acute heart failure -- Cardiorenal syndrome -- Cystatin C -- Glomerular filtration rate; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.13975
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Aims: Acute heart failure (HF) is associated with muscle mass loss, potentially leading to overestimation of kidney function using serum creatinine‐based estimated glomerular filtration rate (eGFRsCr ). Cystatin C‐based eGFR (eGFRCysC ) is less muscle mass dependent. Changes in the difference between eGFRCysC and eGFRsCr may reflect muscle mass loss. We investigated the difference between eGFRCysC and eGFRsCr and its association with clinical outcomes in acute HF patients. Methods and results: A post hoc analysis was performed in 841 patients enrolled in three trials: Diuretic Optimization Strategy Evaluation (DOSE), Renal Optimization Strategies Evaluation (ROSE), and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS‐HF). Intra‐individual differences between eGFRs (eGFRdiff ) were calculated as eGFRCysC –eGFRsCr at serial time points during HF admission. We investigated associations of (i) change in eGFRdiff between baseline and day 3 or 4 with readmission‐free survival up to day 60; (ii) index hospitalization length of stay (LOS) and readmission with eGFRdiff at day 60. eGFRCysC reclassified 40% of samples to more advanced kidney dysfunction. Median eGFRdiff was −4 [−11 to 1.5] mL/min/1.73 m 2 at baseline, became more negative during admission and remained significantly different at day 60. The change in eGFRdiff between baseline and day 3 or 4 was associated with readmission‐free survival (adjusted hazard ratio per standard deviation decrease in eGFRdiff : 1.14, P = 0.035). Longer index hospitalization LOS and readmission were associated with more negative eGFRdiff at day 60 (both P ≤ 0.026 in adjusted models). Conclusions: In acute HF, a marked difference between eGFRCysC and eGFRsCr is present at baseline, becomes more pronounced during hospitalization, and is sustained at 60 day follow‐up. The change in eGFRdiff during HF admission and eGFRdiff at day 60 are associated with clinical outcomes.